Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 323-330, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-8785
ABSTRACT
PURPOSE:
The aim of this study was to develop a pragmatic nomogram for prediction of progressionfree survival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutant non-small cell lung cancer (NSCLC). MATERIALS ANDMETHODS:
A total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who received EGFR TKIs, were enrolled in this study. We developed the nomogram, using a Cox proportional hazard regression model for PFS.RESULTS:
The median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. Multivariate Cox model identified disease status, performance status, chemotherapy line, response to EGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram for PFS was developed, based on these covariates. The concordance index for a nomogram was 0.708, and the calibration was also good.CONCLUSION:
We developed a nomogram, based on clinical characteristics, for prediction of the PFS to EGFR TKI in NSCLC patients with EGFR mutation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Proteínas Tirosina Quinasas
/
Calibración
/
Carcinoma de Pulmón de Células no Pequeñas
/
Nomogramas
/
Quimioterapia
/
Receptores ErbB
/
Neoplasias Pulmonares
/
Metástasis de la Neoplasia
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS